Rademikibart Slashes COPD Treatment Failures by 81% in Phase 2, Paving Way for FDA Talks
CNTB is trading near its 52-week low of $0.98 (11% above the low).
Summary
Connect Biopharma reported positive Phase 2 COPD data for rademikibart, showing an 81% reduction in treatment failure and a 100% reduction in hospital/ED returns. The company will seek FDA alignment on a Phase 3 program.
Key Events · Product Development and Regulatory · CNTB
-
Phase 2 COPD Data Positive
In the 159-patient Seabreeze STAT COPD study, rademikibart reduced treatment failure by 81% (p=0.0122) and new moderate-to-severe exacerbations by 85% (p=0.030) through Week 4 compared with placebo.
-
Hospital/ED Returns Eliminated
Rademikibart cut new ED visits and hospital admissions for exacerbations by 100% (p=0.0137)—zero events in the treatment arm versus 7 (8.6%) in the placebo group.
-
Key Secondary Endpoint Missed
Post-bronchodilator FEV1 at Week 1 (key secondary) was not significant; a 70 mL improvement at Week 4 was clinically meaningful but not statistically significant (p=0.1607).
-
FDA Phase 3 Engagement Planned
The company plans to meet with the FDA to discuss Phase 3 acute and chronic COPD pathways for rademikibart.
Analysis · CNTB · Life Sciences
The full Phase 2 Seabreeze STAT COPD dataset reveals that rademikibart cut treatment failure by 81% (p=0.0122) and completely eliminated hospital or emergency department returns for new exacerbations (100% reduction, p=0.0137) through one month. Management intends to engage the FDA on a Phase 3 program, and its claims analysis points to $6B in potential savings if the drug reaches the market. For a company with a $62M market cap and roughly one year of cash runway, this is a major clinical validation—though the missed significance on the key secondary endpoint (FEV1 at Week 1) tempers the readout.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNTB was trading at $1.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.5M. The 52-week trading range was $0.98 to $3.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.